ASX - By Stock
|
MSB |
Re:
Ann: Information For Retail Shareholders
|
|
hartonij
|
541 |
113K |
0 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
541
|
113K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast CC Transcript 31/8
|
|
hartonij
|
73 |
29K |
2 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
73
|
29K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ceasing to be a substantial holder
|
|
hartonij
|
12 |
5.8K |
2 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
12
|
5.8K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
hartonij
|
88 |
28K |
4 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
88
|
28K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
hartonij
|
1.0K |
386K |
3 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
386K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
hartonij
|
1.0K |
386K |
9 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
386K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
ODAC August 2020 event materials
|
|
hartonij
|
85 |
25K |
0 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
85
|
25K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Voluntary Suspension
|
|
hartonij
|
49 |
31K |
3 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
49
|
31K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
hartonij
|
914 |
284K |
98 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
284K
|
98
|
|
ASX - By Stock
|
MSB |
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
hartonij
|
914 |
284K |
3 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
284K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
hartonij
|
9.3K |
2.6M |
0 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
hartonij
|
9.3K |
2.6M |
0 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
0
|
|
ASX - By Stock
|
VML |
Re:
Interesting VML Article
|
|
hartonij
|
31 |
24K |
4 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
31
|
24K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
hartonij
|
1.0K |
319K |
5 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
1.0K
|
319K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q2 Financial Results and Operational Highlights
|
|
hartonij
|
219 |
55K |
0 |
26/02/22 |
26/02/22 |
ASX - By Stock
|
219
|
55K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q2 Financial Results and Operational Highlights
|
|
hartonij
|
219 |
55K |
4 |
26/02/22 |
26/02/22 |
ASX - By Stock
|
219
|
55K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
hartonij
|
1.0K |
319K |
2 |
20/02/22 |
20/02/22 |
ASX - By Stock
|
1.0K
|
319K
|
2
|
|
ASX - By Stock
|
VML Mining |
Re:
VML General Comments - Chat
|
|
hartonij
|
8.3K |
3.5M |
1 |
17/02/22 |
17/02/22 |
ASX - By Stock
|
8.3K
|
3.5M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Is Rome burning
|
|
hartonij
|
90 |
25K |
0 |
13/02/22 |
13/02/22 |
ASX - By Stock
|
90
|
25K
|
0
|
|
ASX - By Stock
|
LKE |
Re:
LKE towards TOP-5
|
|
hartonij
|
24K |
6.3M |
3 |
23/01/22 |
23/01/22 |
ASX - By Stock
|
24K
|
6.3M
|
3
|
|
ASX - By Stock
|
LKE |
Re:
LKE towards TOP-5
|
|
hartonij
|
24K |
6.3M |
2 |
23/01/22 |
23/01/22 |
ASX - By Stock
|
24K
|
6.3M
|
2
|
|
ASX - By Stock
|
LKE |
Re:
LKE towards TOP-5
|
|
hartonij
|
24K |
6.3M |
2 |
23/01/22 |
23/01/22 |
ASX - By Stock
|
24K
|
6.3M
|
2
|
|
ASX - By Stock
|
LKE |
Re:
LKE towards TOP-5
|
|
hartonij
|
24K |
6.3M |
1 |
23/01/22 |
23/01/22 |
ASX - By Stock
|
24K
|
6.3M
|
1
|
|
ASX - By Stock
|
LKE |
Re:
LKE towards TOP-5
|
|
hartonij
|
24K |
6.3M |
4 |
23/01/22 |
23/01/22 |
ASX - By Stock
|
24K
|
6.3M
|
4
|
|
ASX - By Stock
|
VML Mining |
Re:
VML General Comments - Chat
|
|
hartonij
|
8.3K |
3.5M |
6 |
04/01/22 |
04/01/22 |
ASX - By Stock
|
8.3K
|
3.5M
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
hartonij
|
1.5K |
492K |
1 |
02/01/22 |
02/01/22 |
ASX - By Stock
|
1.5K
|
492K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
|
|
hartonij
|
211 |
72K |
0 |
01/01/22 |
01/01/22 |
ASX - By Stock
|
211
|
72K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
|
|
hartonij
|
211 |
72K |
1 |
01/01/22 |
01/01/22 |
ASX - By Stock
|
211
|
72K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
hartonij
|
408 |
122K |
1 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
122K
|
1
|
|
ASX - By Stock
|
VML Mining |
Re:
VML General Comments - Chat
|
|
hartonij
|
8.3K |
3.5M |
2 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
8.3K
|
3.5M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
hartonij
|
408 |
122K |
2 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
122K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
hartonij
|
10K |
3.0M |
0 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on Chronic Low Back Pain Program
|
|
hartonij
|
340 |
112K |
9 |
01/07/21 |
01/07/21 |
ASX - By Stock
|
340
|
112K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
$90 a share on COVID ARDS Authorization ?
|
|
hartonij
|
260 |
80K |
2 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
260
|
80K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
hartonij
|
10K |
3.0M |
1 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
hartonij
|
10K |
3.0M |
1 |
05/03/21 |
05/03/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
NXL |
Re:
NXL chart
|
|
hartonij
|
460 |
166K |
0 |
14/02/21 |
14/02/21 |
ASX - By Stock
|
460
|
166K
|
0
|
|
ASX - By Stock
|
TWE |
Re:
What is TWE Worth Ex-China?
|
|
hartonij
|
259 |
91K |
0 |
06/12/20 |
06/12/20 |
ASX - By Stock
|
259
|
91K
|
0
|
|